Standard BioTools Inc.

LAB

HealthcareMedical - DevicesNASDAQ

$1.02

Market Cap: $398.18M

Standard BioTools Inc. (LAB) Valuation Summary

Updated May 10, 2026 07:27

Model	Range	Fair Value	Upside
▸ Discounted Cash Flow
Revenue DCF 5Y	$0.02 – $0.59	$0.11	-89.0%
Revenue DCF 10Y	$0.01 – $0.29	$0.01	-99.2%
▸ Trading Multiples
EV/Revenue	$0.61 – $1.94	$0.94	-8.0%

Valuation History

DCF Analysis

Standard BioTools Inc. (LAB) Revenue DCF (5Y)

REVENUE DCF FAIR VALUE

$0.01

Market Price

$1.02

Upside / Downside

-99.2%

Verdict

Overvalued

Using a Revenue DCF model with operating margin convergence from -109.3% to a target of 13.2% over 5 years, discounted at a WACC of 8.1%, Standard BioTools Inc. (LAB) has an intrinsic value of $0.01 per share (range: $0.01 – $0.29).

Key Assumptions

Current Operating Margin

-109.3%

Target Operating Margin

13.2%

WACC

8.1%

Terminal Growth Rate

3.0%

Historical CapEx/Rev

6.3%

Target CapEx/Rev

16.1%

D&A/Revenue

10.7%

Tax Rate

21.0%

Operating margin fades linearly from the current level to the industry target over the 5-year projection. CapEx intensity fades from the historical average to a maintenance level (D&A × 1.5). Tax is only applied when operating income is positive (NOL shield).

Margin Convergence Projection

USD in millions. Mid-year discounting convention.

Year	Revenue	Growth	Op Margin	Op Income	NOPAT	D&A	CapEx	ΔNWC	FCFF	PV(FCFF)
2026	82	-4.2%	-84.8%	-69	-69	9	(6)	-3	-63	-61
2027	84	2.9%	-60.3%	-51	-51	9	(7)	1	-49	-44
2028	88	4.6%	-35.8%	-32	-32	9	(8)	1	-31	-26
2029	89	1.5%	-11.3%	-10	-10	10	(9)	0	-10	-8
2030	80	-10.0%	13.2%	11	8	9	(9)	-3	11	8
2031	72	-10.0%	13.2%	10	8	8	(9)	-2	9	6
2032	67	-7.5%	13.2%	9	7	7	(9)	-2	7	4
2033	64	-4.8%	13.2%	8	7	7	(9)	-1	5	3
2034	62	-2.2%	13.2%	8	6	7	(9)	-0	4	2
2035	63	0.4%	13.2%	8	7	7	(10)	0	3	1

Enterprise Value Bridge

Sum of PV(FCFF)-114

Terminal Value (Gordon Growth at 3.0%)62

PV of Terminal Value30

Enterprise Value-84

(–) Net Debt-87

Equity Value3

(÷) Shares Outstanding382

Fair Value per Share$0.01

Sensitivity Analysis — WACC × Target Operating Margin

WACC \ Target Op. Margin	7.2%	10.2%	13.2%	16.2%	19.2%
6.1%	$-0	$-0	$0	$0	$0
7.1%	$-0	$-0	$0	$0	$0
8.1%	$-0	$-0	$0	$0	$0
9.1%	$-0	$-0	$-0	$0	$0
10.1%	$-0	$-0	$-0	$0	$0

Current price: $1.02. Green = undervalued, Red = overvalued.

Working Capital Assumption

Net Working Capital is modeled at 30.2% of revenue (historical average of receivables + inventory − payables). Changes in NWC (ΔNWC) are computed year-over-year and subtracted from free cash flow.

Standard BioTools Inc. (LAB) Revenue DCF (5Y)

REVENUE DCF FAIR VALUE

$0.11

Market Price

$1.02

Upside / Downside

-89.0%

Verdict

Overvalued

Key Assumptions

Current Operating Margin

-109.3%

Target Operating Margin

13.2%

WACC

8.1%

Terminal Growth Rate

3.0%

Historical CapEx/Rev

6.3%

Target CapEx/Rev

16.1%

D&A/Revenue

10.7%

Tax Rate

21.0%

Margin Convergence Projection

USD in millions. Mid-year discounting convention.

Year	Revenue	Growth	Op Margin	Op Income	NOPAT	D&A	CapEx	ΔNWC	FCFF	PV(FCFF)
2026	82	-4.2%	-84.8%	-69	-69	9	(7)	-3	-64	-62
2027	84	2.9%	-60.3%	-51	-51	9	(9)	1	-51	-45
2028	88	4.6%	-35.8%	-32	-32	9	(11)	1	-34	-28
2029	89	1.5%	-11.3%	-10	-10	10	(13)	0	-14	-10
2030	80	-10.0%	13.2%	11	8	9	(13)	-3	7	5

Enterprise Value Bridge

Sum of PV(FCFF)-140

Terminal Value (Gordon Growth at 3.0%)136

PV of Terminal Value96

Enterprise Value-44

(–) Net Debt-87

Equity Value43

(÷) Shares Outstanding382

Fair Value per Share$0.11

Sensitivity Analysis — WACC × Target Operating Margin

WACC \ Target Op. Margin	7.2%	10.2%	13.2%	16.2%	19.2%
6.1%	$0	$0	$0	$0	$1
7.1%	$-0	$0	$0	$0	$0
8.1%	$-0	$0	$0	$0	$0
9.1%	$-0	$0	$0	$0	$0
10.1%	$-0	$-0	$0	$0	$0

Current price: $1.02. Green = undervalued, Red = overvalued.

Working Capital Assumption

Net Working Capital is modeled at 30.2% of revenue (historical average of receivables + inventory − payables). Changes in NWC (ΔNWC) are computed year-over-year and subtracted from free cash flow.

Trading Multiples

Fair Value

$0.94

Market Price

$1.02

Upside / Downside

-8.0%

Verdict

Overvalued

Using the industry peer median EV/Revenue multiple (trailing + forward), Standard BioTools Inc. (LAB) has a fair value of $0.94 based on 9 comparable companies in the Medical - Devices industry.

EV/Revenue Valuation — Medical - Devices

USD in millions except Fair Price. Subject company highlighted.

	Mkt Cap ($M)	Trailing EV/Revenue	Forward EV/Revenue
Standard BioTools Inc.LAB	389	3.5x	1.8x
Avanos Medical, Inc.AVNS	1,161	1.7x	1.8x
Cullinan Therapeutics, Inc.CGEM	894	44.0x	33.9x
CeriBell, Inc.CBLL	765	8.4x	11.6x
Bioventus Inc.BVS	710	1.7x	1.6x
Cytek Biosciences, Inc.CTKB	593	2.6x	2.7x
Varex Imaging CorporationVREX	496	0.9x	0.9x
OrthoPediatrics Corp.KIDS	457	2.3x	2.0x
ADC Therapeutics S.A.ADCT	445	7.7x	7.7x
Treace Medical Concepts, Inc.TMCI	124	0.6x	0.6x
Industry Median		2.3x	2.0x
(*) Revenue		85	171
= Enterprise Value		194	347
(-) Net Debt		-87	-87
Equity Value		282	435
(/) Outstanding shares		382	382
Fair Price		$1	$1

Selected Fair Value (avg of trailing + forward)

$0.94

-8.0%

Disclaimer: Sweet Value Lab provides estimated intrinsic values for informational purposes only. This is not financial advice. All models rely on assumptions that may not reflect future performance. Always do your own research before making investment decisions.

Model

Range

Fair Value

Upside

▸ Discounted Cash Flow

Revenue DCF 5Y

$0.02 – $0.59

$0.11

-89.0%

Revenue DCF 10Y

$0.01 – $0.29

$0.01

-99.2%

▸ Trading Multiples

EV/Revenue

$0.61 – $1.94

$0.94

-8.0%

DCF Analysis

Standard BioTools Inc. (LAB) Revenue DCF (5Y)

REVENUE DCF FAIR VALUE

$0.01

Market Price

$1.02

Upside / Downside

-99.2%

Verdict

Overvalued

Key Assumptions

Current Operating Margin

-109.3%

Target Operating Margin

13.2%

WACC

8.1%

Terminal Growth Rate

3.0%

Historical CapEx/Rev

6.3%

Target CapEx/Rev

16.1%

D&A/Revenue

10.7%

Tax Rate

21.0%

Margin Convergence Projection

USD in millions. Mid-year discounting convention.

Year	Revenue	Growth	Op Margin	Op Income	NOPAT	D&A	CapEx	ΔNWC	FCFF	PV(FCFF)
2026	82	-4.2%	-84.8%	-69	-69	9	(6)	-3	-63	-61
2027	84	2.9%	-60.3%	-51	-51	9	(7)	1	-49	-44
2028	88	4.6%	-35.8%	-32	-32	9	(8)	1	-31	-26
2029	89	1.5%	-11.3%	-10	-10	10	(9)	0	-10	-8
2030	80	-10.0%	13.2%	11	8	9	(9)	-3	11	8
2031	72	-10.0%	13.2%	10	8	8	(9)	-2	9	6
2032	67	-7.5%	13.2%	9	7	7	(9)	-2	7	4
2033	64	-4.8%	13.2%	8	7	7	(9)	-1	5	3
2034	62	-2.2%	13.2%	8	6	7	(9)	-0	4	2
2035	63	0.4%	13.2%	8	7	7	(10)	0	3	1

Enterprise Value Bridge

Sum of PV(FCFF)-114

Terminal Value (Gordon Growth at 3.0%)62

PV of Terminal Value30

Enterprise Value-84

(–) Net Debt-87

Equity Value3

(÷) Shares Outstanding382

Fair Value per Share$0.01

Sensitivity Analysis — WACC × Target Operating Margin

WACC \ Target Op. Margin	7.2%	10.2%	13.2%	16.2%	19.2%
6.1%	$-0	$-0	$0	$0	$0
7.1%	$-0	$-0	$0	$0	$0
8.1%	$-0	$-0	$0	$0	$0
9.1%	$-0	$-0	$-0	$0	$0
10.1%	$-0	$-0	$-0	$0	$0

Current price: $1.02. Green = undervalued, Red = overvalued.

Working Capital Assumption

Net Working Capital is modeled at 30.2% of revenue (historical average of receivables + inventory − payables). Changes in NWC (ΔNWC) are computed year-over-year and subtracted from free cash flow.

Trading Multiples

Fair Value

$0.94

Market Price

$1.02

Upside / Downside

-8.0%

Verdict

Overvalued

Using the industry peer median EV/Revenue multiple (trailing + forward), Standard BioTools Inc. (LAB) has a fair value of $0.94 based on 9 comparable companies in the Medical - Devices industry.

EV/Revenue Valuation — Medical - Devices

USD in millions except Fair Price. Subject company highlighted.

	Mkt Cap ($M)	Trailing EV/Revenue	Forward EV/Revenue
Standard BioTools Inc.LAB	389	3.5x	1.8x
Avanos Medical, Inc.AVNS	1,161	1.7x	1.8x
Cullinan Therapeutics, Inc.CGEM	894	44.0x	33.9x
CeriBell, Inc.CBLL	765	8.4x	11.6x
Bioventus Inc.BVS	710	1.7x	1.6x
Cytek Biosciences, Inc.CTKB	593	2.6x	2.7x
Varex Imaging CorporationVREX	496	0.9x	0.9x
OrthoPediatrics Corp.KIDS	457	2.3x	2.0x
ADC Therapeutics S.A.ADCT	445	7.7x	7.7x
Treace Medical Concepts, Inc.TMCI	124	0.6x	0.6x
Industry Median		2.3x	2.0x
(*) Revenue		85	171
= Enterprise Value		194	347
(-) Net Debt		-87	-87
Equity Value		282	435
(/) Outstanding shares		382	382
Fair Price		$1	$1

Selected Fair Value (avg of trailing + forward)

$0.94

-8.0%